iPS Cell Breakthroughs Reshaping Drug Discovery for Rare Diseases
Researchers are utilizing patient-derived iPS cells to accelerate drug development and regenerative therapies.
1Transitioning to Human Models
Okano Hideyuki of Keiō University is pioneering the use of induced pluripotent stem (iPS) cells to model neurological diseases. By reprogramming skin or blood cells into patient-specific neurons, researchers bypass the limitations of mouse models. This shift creates a direct bridge from basic laboratory research to practical clinical drug development.
2Overcoming ALS Research Barriers
Amyotrophic lateral sclerosis (ALS) has historically seen high drug development failure rates due to fundamental differences between mouse and human neurons. Okano’s team successfully replicated ALS hallmarks, such as shortened neurites and hyperexcitability, in human-derived cells. This accuracy allows for more reliable testing of potential treatments compared to traditional animal testing.
3Success in Drug Repurposing
The team utilized human iPS cells to identify that ropinirole hydrochloride, a Parkinson’s medication, effectively treats ALS motor neurons. Following a 2018 Nature Medicine publication, Keiō University launched a physician-initiated clinical trial with 20 patients. This rapid transition from lab discovery to clinical testing demonstrates the efficiency of the iPS-based approach.
4Addressing Patient-Specific Variability
Recognizing that ALS pathology varies significantly between individuals, researchers analyzed cell lines from 250 patients. By integrating genomic data with cellular phenotype evaluations, the team aims to use AI to generate personalized drug recommendations. This strategy moves medicine away from uniform treatments toward highly individualized, biology-based prescriptions for complex neurological conditions.
5Regenerative Spinal Cord Therapy
Okano’s team is conducting clinical trials using neural precursor cells derived from iPS cells to treat spinal cord injuries. In a study of four patients with severe quadriplegic paralysis, two showed marked improvement, with one patient regaining enough function to begin walking training. This represents a major milestone in regenerative medicine.
6Regulatory and Industrial Frameworks
Japan’s 2014 Pharmaceuticals and Medical Devices Act facilitates early access to regenerative products by allowing conditional approval while evidence is gathered. To support this, Okano serves as chief scientific officer at K Pharma. The startup is collaborating with Nikon Cell Innovation to establish the industrial infrastructure required for large-scale manufacturing by 2027.
7Expanding to Psychiatric Disorders
The research now extends to schizophrenia, a condition previously difficult to study due to the inability to observe symptoms like hallucinations in animals. By analyzing the electrical activity of neurons derived from patient iPS cells, the team seeks to uncover human-specific disease mechanisms, potentially shortening development timelines from decades to years.
8Future of Regenerative Medicine
Twenty years after the initial development of iPS cells, the field is entering a phase of real-world implementation. While technological progress is rapid, Okano emphasizes that the ultimate challenge remains ensuring equitable access for all patients. The focus is now shifting toward scaling these transformative therapies to reach global clinical standards.
Original article: Nippon.com — iPS Cell Breakthroughs Reshaping Drug Discovery for Rare Diseases